- Q1 2024 2Seventy Bio Inc Earnings Call TranscriptMay 08, 2024$4.48 (-9.68%)Earnings
- Q4 2023 2Seventy Bio Inc Earnings Call TranscriptMar 05, 2024$5.79 (+6.83%)Earnings
- 2Seventy Bio Inc Investor Call TranscriptDec 12, 2023
- Q3 2023 2Seventy Bio Inc Earnings Call TranscriptNov 14, 2023$2.28 (+0.88%)Earnings
- 2Seventy Bio Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2023
- 2Seventy Bio Inc Conference Call TranscriptSep 12, 2023
- Q2 2023 2Seventy Bio Inc Earnings Call TranscriptAug 14, 2023$6.03 (+1.34%)Earnings
- 2seventy bio, Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-14-2023 03:20 PM TranscriptJun 14, 2023
- 2Seventy Bio Inc R&D Deep Dive Presentation (Virtual) TranscriptMay 19, 2023
- Q1 2023 2Seventy Bio Inc Earnings Call TranscriptMay 03, 2023$10.05 (-1.28%)Earnings
- Atara Biotherapeutics Inc, Cellectis SA and 2Seventy Bio Inc at Citi BioPharma Conference- Panel TranscriptSep 07, 2022
- Q2 2022 2Seventy Bio Inc Earnings Call TranscriptAug 10, 2022$17.22 (+3.11%)Earnings
- 2Seventy Bio Inc Focus on bNHL and Solid Tumor Strategy Conference Call TranscriptSep 22, 2021
- 2Seventy Bio Inc Introduction to 2seventy's Pipeline and Next-Gen Multiple Myeloma Strategy Conference Call TranscriptSep 21, 2021
2Seventy Bio Inc Conference Call Transcript
Good day, and thank you for standing by. Welcome to the 2seventy bio Conference Call. (Operator Instructions). Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Liz Pingpank Hickin, Head of Investor Relations. Please go ahead.
Thank you, operator. This morning, 2seventy bio issued two press releases, providing business updates on our restructuring, as well as news regarding the expansion of our partnership with JW Therapeutics. The press releases can be found in the Investors and Media section of the company's website at 2seventybio.com.
Speaking on the call today are Nick Leschly, Chief Kairos Officer; Chip Baird, Chief Operating Officer; and Steve Bernstein, Chief Medical Officer; Philip Gregory, Chief Scientific Officer; and Susan Abu-Absi, Chief Technology Officer, are also on the line for the Q&A section.
As a reminder, today's discussion will include forward-looking statements related to 2seventy bio's current plans and expectations,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)